Danish biotechnology company Zealand Pharma A/S (NASDAQ:ZEAL) (CPH:ZEAL) and German pharmaceutical company Boehringer Ingelheim announced on Tuesday the launch of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).
It's hoped that the once-weekly therapy may offer additional benefits for both chronic weight management and NASH improvement and prevention of the progression to cirrhosis compared to currently available treatments with mono GLP-1 agonist compounds.
The compound is also being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus.
Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand's expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim's expertise in the research and development of novel medicines for cardiometabolic diseases.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval